AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,350 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
How did ATRC's recent EPS compare to expectations?
The most recent EPS for AtriCure Inc is $0.0, beating expectations of $-0.06.
How did AtriCure Inc ATRC's revenue perform in the last quarter?
AtriCure Inc revenue for the last quarter is $0.0
What is the revenue estimate for AtriCure Inc?
According to 11 of Wall street analyst, the revenue estimate of AtriCure Inc range from $160.65M to $145.63M
What's the earning quality score for AtriCure Inc?
AtriCure Inc has a earning quality score of B+/52.019577. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does AtriCure Inc report earnings?
AtriCure Inc next earnings report is expected in 2026-08-03
What are AtriCure Inc's expected earnings?
AtriCure Inc expected earnings is $142.6M, according to wall-street analysts.
Did AtriCure Inc beat earnings expectations?
AtriCure Inc recent earnings of $141.24M does not beat expectations.